{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:21:46Z","timestamp":1792801306191,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00702-019-02026-8","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T13:02:50Z","timestamp":1561035770000},"page":"871-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Polypharmacy in Parkinson\u2019s disease: risks and benefits with little evidence"],"prefix":"10.1007","volume":"126","author":[{"given":"I.","family":"Csoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Woitalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-0790","authenticated-orcid":false,"given":"U.","family":"W\u00fcllner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"10103","key":"2026_CR1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Foltynie T et al (2017) Exenatide (Astra-Zeneca) once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675","journal-title":"Lancet"},{"issue":"5","key":"2026_CR203","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B (2006) Depression\/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 253(5):601\u20137","journal-title":"J Neurol."},{"key":"2026_CR37","unstructured":"Barnes PJ, Drazen JM, Rennard SI, Thomson NC (eds) (2009) Asthma and COPD. In: Basic mechanisms and clinical management, 2nd edn. Academic Press"},{"issue":"10","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrneurol.2015.150","volume":"11","author":"P Brundin","year":"2015","unstructured":"Brundin P, Wyse R (2015) Parkinson disease: laying the foundations for disease-modifying therapies in PD. Nat Rev Neurol 11(10):553\u2013555","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2026_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","volume":"989","author":"WJ Burke","year":"2003","unstructured":"Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde: implications for Parkinson\u2019s disease pathogenesis. Brain Res 989(2):205\u2013213","journal-title":"Brain Res"},{"issue":"5777","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/bmj.3.5777.729","volume":"3","author":"DB Calne","year":"1971","unstructured":"Calne DB, Reid JL, Vakil SD, Rao S, Petrie A, Pallis CA, Gawler J, Thomas PK, Hilson A (1971) Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J 3(5777):729\u2013732","journal-title":"Br Med J"},{"issue":"7148","key":"2026_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ (2007) \u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease. Nature 447(7148):1081\u20131086","journal-title":"Nature"},{"issue":"2","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles LD (2018) Repeated-dose oral N-acetylcysteine in Parkinson\u2019s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol 58(2):158\u2013167","journal-title":"J Clin Pharmacol"},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nbd.2017.07.007","volume":"106","author":"TJ Collier","year":"2017","unstructured":"Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D et al (2017) Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiol Dis 106:191\u2013204","journal-title":"Neurobiol Dis"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","volume":"11","author":"MH Corrigan","year":"2000","unstructured":"Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11:58\u201365","journal-title":"Depression Anxiety"},{"issue":"4","key":"2026_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/1871527316666170124165222","volume":"16","author":"L Dezsi","year":"2017","unstructured":"Dezsi L, Vecsei L (2017) Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 16(4):425\u2013439","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"2026_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000131893","volume":"60","author":"EV Encarnacion","year":"2008","unstructured":"Encarnacion EV, Hauser RA (2008) Levodopa-induced dyskinesias in Parkinson\u2019s disease: etiology, impact on quality of life, and treatments. Eur Neurol 60(2):57\u201366","journal-title":"Eur Neurol"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fphar.2016.00340","volume":"7","author":"JPM Finberg","year":"2016","unstructured":"Finberg JPM, Rabey JM (2016) Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol 7:340\u2013354","journal-title":"Front Pharmacol"},{"issue":"8","key":"2026_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","volume":"14","author":"FS-ZONE Investigators","year":"2015","unstructured":"FS-ZONE Investigators (2015) NINDS Exploratory Trials in Parkinson Disease (NET-PD). Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14(8):795\u2013803","journal-title":"Lancet Neurol"},{"issue":"3","key":"2026_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y (2016) Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):249\u2013258","journal-title":"Lancet Neurol"},{"key":"2026_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022854","author":"X Huang","year":"2011","unstructured":"Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H, The Parkinson Study Group DATATOP Investigators (2011) Serum cholesterol and the progression of Parkinson\u2019s disease: results from DATATOP. PLoS One. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0022854","journal-title":"PLoS One"},{"issue":"4","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/brain\/awr028","volume":"134","author":"A Imtiaz","year":"2011","unstructured":"Imtiaz A, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ (2011) Glutamate NMDA receptor dysregulation in Parkinson\u2019s disease with dyskinesias. Brain 134(4):979\u2013986","journal-title":"Brain"},{"issue":"2","key":"2026_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.14802\/jmd.18005","volume":"11","author":"A Kim","year":"2018","unstructured":"Kim A, Kim YE, Yun JY, Kim HJ, Yang HJ, Lee WW, Shin CW, Park H, Jung YJ, Kim A, Kim Y, Jang M, Jeon B (2018) Amantadine and the risk of dyskinesia in patients with early Parkinson\u2019s disease: an open-label, pragmatic trial. J Mov Disord 11(2):65\u201371","journal-title":"J Mov Disord"},{"key":"2026_CR17","volume-title":"Taiwan; abstract at AD\/PD","author":"Y-C Kuan","year":"2017","unstructured":"Kuan Y-C (2017) Taiwan; abstract at AD\/PD. Taipei Medical University, New Taipei City"},{"key":"2026_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejphar.2018.12.027","volume":"845","author":"VB Kumar","year":"2019","unstructured":"Kumar VB, Hsu FF, Lakshmi VM, Gillespie KN, Burke WJ (2019) Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced \u03b1-synuclein aggregation and toxicity: implication for Parkinson neuroprotective therapy. Eur J Pharmacol 845:65\u201373","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"2026_CR19","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.2013.280490","volume":"310","author":"JR Lam","year":"2013","unstructured":"Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310(22):2435\u20132442","journal-title":"JAMA"},{"issue":"8","key":"2026_CR200","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nrneurol.2015.126","volume":"11","author":"AF Leentjens","year":"2015","unstructured":"Leentjens AF (2015) Parkinson disease: Depression-risk factor or early symptom in Parkinson disease? Nat Rev Neurol. 11(8):432\u20133","journal-title":"Nat Rev Neurol."},{"issue":"4","key":"2026_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/mds.20685","volume":"21","author":"CL Leibson","year":"2006","unstructured":"Leibson CL, Maraganore DM, Bower JH, Ransom JE, O\u2019Brien PC, Rocca WA (2006) Comorbid conditions associated with Parkinson\u2019s disease: a population-based study. Mov Dis 21(4):446\u2013455. \n                    https:\/\/doi.org\/10.1002\/mds.20685","journal-title":"Mov Dis"},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000438824","volume":"74","author":"Z Li","year":"2015","unstructured":"Li Z, Yu Z, Zhang J, Wang J, Sun C, Wang P, Zhang J (2015) Impact of rivastigmine on cognitive dysfunction and falling in Parkinson\u2019s disease patients. Eur Neurol 74:86\u201391","journal-title":"Eur Neurol"},{"issue":"5","key":"2026_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"J McNeill","year":"2014","unstructured":"McNeill J, Magalhaes J, Shen C, Chau K-Y, Hughes D, Mehta A, Foltynie T, Cooper MJ, Abramov AY, Gegg M, Schapira AHV (2014) Brain 137(5):1481\u20131495","journal-title":"Brain"},{"issue":"10","key":"2026_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","volume":"72","author":"M Menza","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10):886\u2013892","journal-title":"Neurology"},{"issue":"Suppl 2","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1468-1331.2008.02214.x","volume":"15","author":"JC M\u00f6ller","year":"2008","unstructured":"M\u00f6ller JC, Eggert KM, Unger M, Odin P, Chaudhuri KR, Oertel WH (2008) Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol 15(Suppl 2):15\u201323","journal-title":"Eur J Neurol"},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1586\/14737175.8.6.957","volume":"8","author":"T Muller","year":"2008","unstructured":"Muller T (2008) Role of homocysteine in the treatment of Parkinson\u2019s disease. Expert Rev Neurother 8:957\u2013967","journal-title":"Expert Rev Neurother"},{"key":"2026_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/ncn3.126","volume":"2","author":"M Murata","year":"2014","unstructured":"Murata M, Hasegawa K, Kanazawa I, Shirakura K, Kochi K, Shimazu R, For the Zonisamide PD Study Group (2014) Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease. Neurol Clin Neurosci 2:201\u2013203","journal-title":"Neurol Clin Neurosci"},{"issue":"8","key":"2026_CR27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","volume":"66","author":"S P\u00e5lhagen","year":"2006","unstructured":"P\u00e5lhagen S, Heinonen E, H\u00e4gglund J, Kaugesaar T, M\u00e4ki-Ikola O, Palm R, Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66(8):1200\u20131206","journal-title":"Neurology"},{"key":"2026_CR28","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.bbagen.2016.06.018","volume":"1860","author":"R Paul","year":"2016","unstructured":"Paul R, Borah A (2016) l-DOPA-induced hyperhomocysteinemia in Parkinson\u2019s disease: elephant in the room. Biochim Biophys Acta 1860:1989\u20131997","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2026_CR29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","volume":"48","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Parkinson Study Group. Neurology 48(4):1070\u20131077","journal-title":"Neurology"},{"issue":"16","key":"2026_CR201","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","volume":"78","author":"IH Richard","year":"2012","unstructured":"Richard IH, McDermott MP, Kurlan R et al (2012) For SAD-PD Study Group A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78(16):1229\u20131236","journal-title":"Neurology"},{"issue":"3","key":"2026_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","volume":"19","author":"JA Santiago","year":"2013","unstructured":"Santiago JA, Potashkin JA (2013) Shared dysregulated pathways lead to Parkinson\u2019s disease and diabetes. Trends Mol Med 19(3):176\u2013186. \n                    https:\/\/doi.org\/10.1016\/j.molmed.01.002","journal-title":"Trends Mol Med"},{"key":"2026_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fnagi.2017.00394","volume":"9","author":"JA Santiago","year":"2017","unstructured":"Santiago JA, Bottero V, Potashkin JA (2017) Biological and clinical implications of comorbidities in Parkinson\u2019s disease. Front Aging Neurosci 9:394. \n                    https:\/\/doi.org\/10.3389\/fnagi.2017.00394","journal-title":"Front Aging Neurosci"},{"key":"2026_CR32","first-page":"1","volume":"3","author":"MA Schreiber","year":"2013","unstructured":"Schreiber MA, Thompson AW (2013) The pharmacologic management of depression in Parkinson\u2019s disease. Degener Neurol Neuromuscul Dis 3:1\u20139","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"11","key":"2026_CR33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/ncpneuro0934","volume":"4","author":"KM Shannon","year":"2008","unstructured":"Shannon KM (2008) Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists. Nat Clin Pract Neurol 4(11):590\u2013591","journal-title":"Nat Clin Pract Neurol"},{"issue":"3 Suppl 1","key":"2026_CR34","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1002\/ana.410440724","volume":"44","author":"I Shoulson","year":"1998","unstructured":"Shoulson I (1998) DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann Neurol 44(3 Suppl 1):S160\u2013S166","journal-title":"Ann Neurol"},{"issue":"7","key":"2026_CR35","doi-asserted-by":"publisher","first-page":"e005158","DOI":"10.1136\/bmjopen-2014-005158","volume":"4","author":"K Stubendorff","year":"2014","unstructured":"Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E (2014) Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson\u2019s disease with dementia: a prospective study. BMJ Open 4(7):e005158","journal-title":"BMJ Open"},{"issue":"12","key":"2026_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40263-016-0393-9","volume":"30","author":"T Swart","year":"2016","unstructured":"Swart T, Hurley M (2016) Calcium channel antagonists as disease-modifying therapy for Parkinson\u2019s disease: therapeutic rationale and current status. CNS Drugs 30(12):1127\u20131135","journal-title":"CNS Drugs"},{"issue":"6","key":"2026_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.46.6.1551","volume":"46","author":"RJ Uitti","year":"1996","unstructured":"Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson\u2019s disease. Neurology 46(6):1551\u20131556","journal-title":"Neurology"},{"key":"2026_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2008.06.055","volume":"442","author":"S Vautier","year":"2008","unstructured":"Vautier S, Milane A, Fernandez C et al (2008) Interactions between antiparkinsonian drugs and ABCB1\/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model. Neurosci Lett 442:19\u201323","journal-title":"Neurosci Lett"},{"key":"2026_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neulet.2016.11.007","volume":"636","author":"Y Xie","year":"2017","unstructured":"Xie Y, Feng H, Peng S, Xiao J, Zhang J (2017) Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson\u2019s disease: a meta-analysis. Neurosci Lett 636:190\u2013195","journal-title":"Neurosci Lett"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02026-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02026-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02026-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T10:25:45Z","timestamp":1596104745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02026-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02026-8","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}